Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density by Veldhuis-Vlug, A.G. et al.
ORIGINAL ARTICLE
Association of polymorphisms in the beta-2 adrenergic receptor
gene with fracture risk and bone mineral density
A. G. Veldhuis-Vlug & L. Oei & P. C. Souverein & M. W. T. Tanck &
F. Rivadeneira & M. C. Zillikens & P. W. Kamphuisen &
A.H. Maitland - van der Zee & M. C. H. de Groot & A. Hofman &
A. G. Uitterlinden & E. Fliers & A. de Boer & P. H. Bisschop
Received: 20 October 2014 /Accepted: 20 February 2015 /Published online: 25 April 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Summary Signaling through the beta-2 adrenergic receptor
(B2AR) on the osteoblast influences bone remodeling in ro-
dents. In the B2AR gene, three polymorphisms influence re-
ceptor function. We show that these polymorphisms are not
associated with fracture risk or bone mineral density in the
UCP, Rotterdam Study, and GEFOS cohorts.
Introduction Signaling through the beta-2 adrenergic receptor
(B2AR) on the osteoblast influences bone remodeling in ro-
dents. In the B2AR gene, three polymorphisms are known to
influence receptor function in vitro and in vivo (rs1042713,
rs1042714, and rs1800888). We examined the role of these
polymorphisms in the B2AR gene on human bone
metabolism.
Methods We performed nested case–control studies to deter-
mine the association of these polymorphisms with fracture
risk in the Utrecht Cardiovascular Pharmacogenetics (UCP)
cohort and in three cohorts of the Rotterdam Study. We also
determined the association of these polymorphisms with bone
mineral density (BMD) in the GEFOS Consortium. UCP con-
tains drug-dispensing histories from community pharmacies
linked to national registrations of hospital discharges in the
Netherlands. The Rotterdam Study is a prospective cohort
study investigating demographics and risk factors of chronic
diseases. GEFOS is a large international collaboration study-
ing the genetics of osteoporosis. Fractures were defined by
ICD-9 codes 800–829 in the UCP cohort (158 cases and
2617 unmatched controls) and by regular X-ray examinations,
general practitioner, and hospital records in the Rotterdam
Study (2209 cases and 8559 unmatched controls). BMD was
measured at the femoral neck and lumbar spine using dual-
energy X-ray absorptiometry in GEFOS (N=32,961).
Results Meta-analysis of the two nested case–control studies
showed pooled odds ratios of 0.98 (0.91–1.05, p=0.52), 1.04
(0.97–1.12, p=0.28), and 1.16 (0.83–1.62, p=0.38) for the
associations between rs1042713, rs1042714, and rs1800888
per minor allele and fractures, respectively. There were no
significant associations of the polymorphisms and BMD in
GEFOS.
Conclusion In conclusion, polymorphisms in the beta-2 ad-
renergic receptor gene are not associated with fracture risk or
BMD.
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Introduction
The sympathetic nervous system (SNS) influences bone re-
modeling in rodents by signaling through the beta-2 adrener-
gic receptor (B2AR) on the osteoblast. Osteoblast-specific
deletion of the B2AR decreased bone resorption and led to
an increase in bone mineral density [1]. To date, it is uncertain
whether this mechanism also exists in humans. Retrospective
observational studies in humans on the association of beta-
blockers and fracture risk reported conflicting results, yet a
recent meta-analysis showed a reduction in fracture risk with
a relative risk around 0.85 [2].
The B2AR is a G-protein coupled receptor (GPCR). Bind-
ing of a ligand to the receptor leads to activation of the enzyme
adenylate cyclase and generation of cyclic adenosine
monophosphate (cAMP). Ligand binding also leads to phos-
phorylation of GPCR kinases which promotes downregula-
tion of the receptor [3]. The intronless B2AR gene is localized
on chromosome 5q31-32 and encodes for a protein of 413
amino acids. In 1993, the first single nucleotide polymor-
phism (SNP) in the B2AR gene was reported [4], and since
then, many more SNPs have been identified. Four SNPs are
non-synonymous and three of these are in the coding region of
the gene [5] on amino acid positions 16 (Arg16Gly;
rs1042713), 27 (Gln27Glu; rs1042714), and 164 (Thr164Ile;
rs1800888). The SNP on position 164 has not been found in
humans homozygously and has a low minor allele frequency
(<5 %) [6]. The B2AR gene is highly evolutionary conserved,
the mouse and human gene are 88 % similar (comparison
based on amino acids), and this also applies to the region
surrounding the polymorphisms.
In vitro [7, 8] and in vivo [9] experiments have shown that
the Thr164Ile polymorphism lowers the binding affinity and
activation of cAMP, leading to a signaling defect of the recep-
tor. For the Arg16Gly and Gln27Glu polymorphisms, the
Gly16 variant was shown to be more susceptible to agonist-
induced downregulation whereas the Glu27 is more resistant.
The Gly16 variant dominates the phenotype when both vari-
ants are present (reviewed in [10–13]). Clinical research has
extensively shown an effect of B2AR gene polymorphisms in
cardiovascular therapy [14] and asthma [15, 16], and there are
reports of B2AR gene polymorphisms influencing obesity
[17], healthy aging [18], bacterial meningitis [19], and
Graves’ disease [20].
Since these studies show that the function of the B2AR can
be influenced by polymorphisms, we hypothesized that these
polymorphisms in the B2AR gene could also have an effect on
bone metabolism. To examine the role of beta-adrenergic sig-
naling in human bone metabolism, we investigated the asso-
ciation of these polymorphisms in the B2AR gene with frac-
ture risk in the Utrecht Cardiovascular Pharmacogenetics
(UCP) cohort and the Rotterdam Study cohorts. We also in-
vestigated the association with bone mineral density (BMD)
using the meta-analysis of genome-wide association (GWA)
data of the GEFOS consortium.
Materials and methods
Study design
We conducted nested case–control studies to assess the influ-
ence of SNPs in the B2AR gene on fracture risk in the Utrecht
Cardiovascular Pharmacogenetics cohort and the Rotterdam
Study cohorts (www.epib.nl/research/ergo.htm). In addition,
we studied the influence of the SNPs in the B2AR gene on
bone mineral density using the meta-analysis of GWA data of
the GEFOS consortium (www.gefos.org).
The study was carried out in accordance with the principles
of the Declaration of Helsinki. The Institutional Review
Boards of the University Medical Center Utrecht (UCP) and
of the Erasmus Medical Center (Rotterdam Study) in the
Netherlands granted approval for the study. All subjects pro-
vided written informed consent. For the GEFOS Consortium,
all studies were approved by their respective institutional
ethics review committees, and all participants provided writ-
ten informed consent.
Study populations
Utrecht cardiovascular pharmacogenetics cohort
Design and population The Utrecht Cardiovascular Pharma-
cogenetics cohort enrolled participants from the Pharmaco-
Morbidity Record Linkage System (PHARMO RLS; Institute
for Drug Outcome Research, www.pharmo.nl). PHARMO
RLS is a registry linking among others pharmacy records to
hospital discharge records of over three million individuals in
the Netherlands continuously from 1985 onwards. The
pharmacy records contain information on drugs prescribed,
dispensing date, amount of drug dispensed, dose regimen,
and prescription length. Drug prescriptions were coded
according to the Anatomical Therapeutic Chemical
Classification (ATC), and hospital discharge diagnoses were
coded according to the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM). Recruitment of subjects in the UCP was described
previously [21]. Briefly, within all patients with
hypertension and/or hypercholesterolemia in the PHARMO
database, all myocardial infarction patients and matched
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controls (1 up to 12 matching for age, sex, and area of resi-
dence) were selected. In addition, a cohort of type 2 diabetes
mellitus patients was selected. Community pharmacies re-
cruited these subjects and after informed consent DNA and
questionnaire information was collected. All patients selected
in the context of these studies were used in the final UCP
cohort (N=5126), and 2775 subjects had complete informa-
tion on the relevant SNPs and medication. Patients were en-
rolled between 1985 and 2005, and median follow-up was
12 years (IQR 10.5–16.3 years).
Genotyping Participants either collected a buccal cell sample
as described previously [22] or received an Oragene collection
kit (DNA Genotek, Ottawa, Canada). DNAwas extracted ac-
cording to the manufacturer’s instructions. Genotyping was
performed with the Illumina (Illumina Inc. San Diego, CA,
USA) IBS Candidate Gene array version 3, representing 53,
831 SNPs [23]. SNPs with a call rate <95 %, related samples,
contaminated samples, and population outliers were excluded
using PLINK [24] and EIGENSTRAT [25].
Case definition Cases were defined by fracture during follow-
up, and this was assessed by first hospital admission for frac-
ture (ICD-9-CM codes 800 to 829).We distinguished the skull
(800–804), vertebra (805–806), rib (807), pelvis (808),
clavicula (810), scapula (811), humerus (812), arm (813),
hand (814–817), hip (820–821), patella (822), leg (823–
824), foot (825–826), and unspecified (809, 818–819, 827–
829) fractures. All other subjects were defined as controls.
Determinants Age was determined at baseline. Medication
use was classified as present if used ever during follow-up.
Rotterdam study
Design and population The Rotterdam Study is a prospective,
population-based cohort initiated to study the determinants of
chronic diseases, including osteoporosis. The study design has
been described previously [26]. Briefly, the cohort included
inhabitants 45 years of age and over of the Ommoord district
in the city of Rotterdam in the Netherlands from 1990 on-
wards. To the original cohort (Rotterdam Study I), two exten-
sions were added (Rotterdam Study II and Rotterdam Study
III) in 2000 and 2006 and the total cohort now includes almost
15,000 individuals. At baseline, a home interview on medical
history, risk factors for chronic diseases, and medication use
was taken by trained interviewers and subjects underwent a
clinical examination and laboratory and radiological investi-
gations in a research center, and these examinations were re-
peated every 3 to 4 years. Of 10,768 subjects, medical infor-
mation and relevant SNPs were complete and these were in-
cluded in the present analysis,
Genotyping Rotterdam Study samples were genotyped with
the Illumina (Illumina Inc. San Diego, CA, USA) Infinium
HumanHap550 HumanHap610 Beadchips. Participants miss-
ing DNA or information on body weight and height and sam-
ples with gender mismatch with typed X-linked markers, ex-
cess autosomal heterozygosity >0.336∼FDR>0.1 %, dupli-
cates and/or first- or second-degree relatives using IBS prob-
abilities >97 % and ethnic outliers using IBS distances>3SD
from PLINK [25] were excluded. SNPs with a call rate
<97.5 % and minor allele frequency <0.01 were excluded.
Next, the data were imputed with reference to the International
HapMap Project [27] (CEU panel release 22), and SNPs with
an imputation quality of R2 <0.3 were removed. This resulted
in a total of 2,448,227 SNPs in Rotterdam Study I, 2,448,227
SNPs in Rotterdam Study II, and 2,448,227 SNPs in Rotter-
dam Study III. rs1042713 was directly genotyped, and
rs1042714 (R2 quality score 0.97 in all three cohorts) and
rs1800888 (R2 quality score ranged from 0.63 to 0.74) were
imputed.
Case definition Cases were defined by fracture during follow-
up. Fractures were assessed in the Rotterdam Study I and
Study II by X-ray examinations (digitalized Fuji FCR system
(FUJIFILM Medical Systems)) of vertebral bodies, hips,
knees, and hand/wrist performed during the periodic exami-
nations. Incident clinical fractures were obtained from com-
puterized records of the general practitioners and hospital reg-
istries which were regularly checked by research physicians
who reviewed and coded the fracture information [26]. In the
Rotterdam Study III, fracture was assessed by vertebral frac-
ture assessment using dual-energy X-ray absorptiometry. All
other subjects were defined as controls.
Determinants Age and medication use was determined at
baseline.
GEFOS
Design GEFOS or the Genetic Factors for Osteoporosis Con-
sortium is a collaboration of several international research
groups studying the genetics of osteoporosis using meta-
analysis of GWA data with high-density SNP arrays. GEFOS
has released summary data from their 2012 meta-analyses on
femoral neck and lumbar spine bone mineral density tested in
32,961 subjects included from 17 studies (http://www.gefos.
org/?q=content/data-release).
Genotyping In brief, genotyping and imputation were
performed using standard protocols to facilitate meta-
analysis, and quality control was carried out for each
study independently. An extensive description can be found
in [28].
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Bone mineral density assessment Lumbar spine and femoral
neck bone mineral density were measured in all cohorts using
dual-energy X-ray absorptiometry following standard proto-
cols, described in detail in [28].
Data analysis
Analyses were performed with SPSS for Windows (version
19.0; SPSS Inc., Chicago, IL) for UCP andMACH2DAT [29]
run on the GRIMPweb-based interface [30] for the Rotterdam
Study. Differences between cases and controls were tested
with a Student’s t test. To assess the association between ge-
notypes and fracture risk, logistic regression analysis was
used. The analysis of the Rotterdam Study was adjusted for
age, sex, length, and weight. To generate adjusted odds ratios
in the UCP analysis, we included sex as a categorical variable
and age as a categorical variable since the relation with frac-
ture risk was non-linear and medication use as a categorical
variable. The following medication groups were added to the
model: glucocorticoids, bone-modifying drugs, anti-depres-
sants, anti-epileptics, benzodiazepines, non-steroidal anti-in-
flammatory drugs, antidiabetics, antihypertensives (ACE in-
hibitors, AT2 antagonists, diuretics, alpha blockers, and calci-
um antagonists), and beta-blockers. There was no deviation
from additivity; therefore, we used an additive genetic model.
To test for haplotype effects in the UCP cohort, we used R
statistical software for Windows (version 2.15 [31], package:
Haplostats [32]). Meta-analysis was performed using Review
Manager (version 5.2, Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration 2012). Inverse variance
with fixed effect was used to estimate the pooled odds ratio
and the 95 % confidence interval. All tests were two-sided,
and a p value of <0.05 was considered significant. In GEFOS,
genome-wide association analysis for FN- and LS-BMD was
carried out using sex-specific and age- and weight- and prin-
cipal component-adjusted standardized residuals assuming an
additive genetic model [28]. The final data files included p-
values after meta-analysis using regression coefficients (beta
and standard error) and after correction for inflation of test
statistics using genomic control both at the individual study
level and again after meta-analysis.
Power calculation
With the present sample size of 2617 controls and 158 cases
(ratio 16.6) in the UCP Study, odds ratios larger than 1.4 and
3.1 could be detected with 80 % power for SNPs with minor
allele frequencies of 0.37 and 0.01, respectively. In the Rot-
terdam Study, the sample size of 8559 controls and 2209 cases
(ratio 3.9) allows odds ratios larger than 1.1 and 1.53 to be
detected with 80 % power for SNPs with a MAF of 0.37 or
0.01, respectively. For both calculations, a logistic regression
model, an additive genetic model, and a two-sided signifi-
cance level of 0.05 were used.
Results
Study populations
The UCP cohort consisted of 158 cases and 2617 controls.
The Rotterdam Study I included 1575 cases and 4117 con-
trols, Rotterdam Study II 129 cases and 2021 controls, and
Rotterdam Study III 505 cases and 2421 controls. Character-
istics of the cases and controls per cohort are shown in Table 1.
Cases were significantly more likely to be female and older
compared to controls, as expected. Furthermore, in the UCP
cohort, cases more often used sleep and antipsychotic medi-
cation and non-steroidal anti-inflammatory drugs than con-
trols, although absolute numbers of users were small. Con-
versely, controls were prescribed significantly more frequent-
ly beta-blockers and other antihypertensive and antidiabetic
medication. Corticosteroid and bone-modifying drug pre-
scriptions were rare among cases and controls. Genotype did
not deviate from Hardy-Weinberg equilibrium. Minor allele
frequencies were 0.37 (rs1042713 A allele), 0.45 (rs1042714
G allele), and 0.01 (rs1800888 T allele) both in the UCP,
Rotterdam Study, and GEFOS, which is in accordance with
previously published reports [10].
Beta-2 adrenergic receptor genotype and fracture
In UCP, 158 fractures were recorded, one third of which were
hip fractures, one of the major osteoporotic fractures. In the
Rotterdam Study I, 1575 fractures were recorded, of which
vertebral fractures accounted for a quarter and wrist and hip
fractures combined for a third of all fractures. The Rotterdam
Study II contained 129 fractures, a quarter of which were wrist
and hip fractures and almost 20 % vertebral fractures. Five
hundred fifty fractures were included in the Rotterdam Study
III, all of which were vertebral fractures (Table 2).
We did not find an association between B2AR genotype
and fracture neither in the UCP cohort nor in the Rotterdam
Study (Table 3). In UCP, we adjusted for age, sex, and med-
ication use, and we performed a haplotype analysis since
strong linkage disequilibrium exists between the SNPs; how-
ever, the outcome remained the same. In UCP, we also ana-
lyzed the data as a cohort study; however, the fracture relative
risks using Cox proportional hazard models were similar to
the odds ratios. Meta-analysis of the combined nested case–
control studies estimated a pooled odds ratio of 0.98 (95 % CI
0.91–1.05, p=0.52), 1.04 (0.97–1.12, p=0.28), and 1.16
(0.83–1.62, p=0.38) for rs1042713, rs1042714, and
rs1800888 per copy of the minor allele, respectively (Fig. 1).
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Beta-2 adrenergic receptor genotype and bone mineral density
The GEFOS consortium reported p values after meta-analysis
for FN-BMD of 0.924, 0.852, and 0.737 and for LS-BMD of
0.635, 0.364, and 0.346 for rs1042713, rs1042714, and
rs1800888, respectively.
Discussion
In both the Utrecht Cardiovascular Pharmacogenetics and the
Rotterdam Study cohorts, there were no associations of poly-
morphisms in the beta-2 adrenergic receptor with fracture risk.
In the GEFOS consortium, there was also no association of
B2AR alleles with bone mineral density.
The B2AR is involved in bone metabolism in rodents.
B2AR knockout mice have an increased bone mass and treat-
ment with beta-blockers or beta-agonists increases and de-
creases bone mass respectively [1, 33–36]. The B2AR gene
is highly evolutionary conserved; the mouse and human genes
are 88 % similar (comparison based on amino acids), and this
also applies to the region surrounding the polymorphisms
(h t t p : / / g enome .uc sc . edu / cg i -b in /hgTracks?db=
hg19&position=chr5%3A148206156-148208197&hgsid=
406908755_GVOKV49jJeWv0lNk5TyiXyon0z8p). In
humans, the role of the B2AR in bone metabolism remains
speculative. Epidemiological studies investigating the
association between beta-blocker treatment and fracture risk
presented inconclusive results, although a recent meta-
analysis showed some fracture reduction with beta-blocker
treatment [2]. Two recent studies support a role of the SNS
in the regulation of human bone metabolism. We showed that
bone resorption is increased in pheochromocytoma patients
and normalized following adrenalectomy [37]. Pheochromo-
cytomas are tumors of the adrenal gland, producing catechol-
amines, the natural ligands of adrenergic receptors. Farr et al.
showed that sympathetic activity, as measured with
Table 1 Characteristics cases and controls per cohort
UCP Rotterdam Study I Rotterdam Study II Rotterdam Study III
Control Case p value Control Case p value Control Case p value Control Case p value
Number 2617 158 4117 1575 2021 129 2421 505
Sex, % male 71 53 <0.001 47 27 <0.001 46 31 <0.001 42 54 <0.001
Age mean, years (SD) 58 (10.7) 60 (11.1) 0.009 68 (8.8) 70 (8.6) <0.001 65 (7.8) 68 (9.1) <0.001 57 (6.6) 58 (7.4) 0.007
Medication use, %
Beta-blockers 79 58 <0.001 15 13 0.080 15 16 0.519 14 17 0.096
Other antihypertensives 77 65 0.001 14 12 0.042 1 2 0.055 0 1 0.053
Corticosteroids 8 10 0.443 2 2 1.000 1 2 0.078 1 1 0.980
Bone-modifying drugs 8 6 0.754 0 0 NA 1 2 0.262 1 3 <0.001
Antidiabetic drugs 31 18 <0.001 4 5 0.093 5 8 0.025 4 6 0.354
Antidepressant drugs 6 7 0.604 2 2 0.535 5 6 0.530 7 6 0.449
Antipsychotic drugs 1 1 1.0 14 18 <0.001 10 12 0.152 10 6 0.006
Antiepileptic drugs 4 4 0.503 0 1 1.000 14 17 0.840 14 26 0.074
Sleep medication 15 22 0.017 14 15 0.604 13 20 0.006 9 6 0.038
NSAIDs 10 16 0.030 25 26 0.365 11 10 0.707 14 10 0.018
Immunosuppressive drugs 1 3 0.125 0 0 1.000 0 0 NA 1 1 0.925
Characteristics of the cases and controls of the UCP and Rotterdam Study cohorts
NA not applicable
Table 2 Fracture type
UCP
(N=158)
RS-I
(N=1575)
RS-II
(N=129)
RS-III
(N=505)
Skull, N (%) 6 (4) 56 (3) 2 (1) ND
Vertebrae 8 (5) 509 (25) 30 (18) 505 (100)
Rib 19 (12) 82 (4) 11 (7) ND
Pelvis 5 (3) 61 (3) 4 (2) ND
Clavicula 3 (2) ND ND ND
Scapula 0 ND ND ND
Humerus 4 (3) 149 (7) 10 (6) ND
Arm 14 (9) 138 (7) 10 (6) ND
Wrist ND 329 (16) 26 (16) ND
Hand 9 (6) 127 (6) 20 (12) ND
Hip 54 (34) 355 (17) 16 (10) ND
Patella 6 (4) ND ND ND
Leg 27 (17) 100 (5) 18 (11) ND
Foot 2 (1) 57 (3) 8 (5) ND
Unspecified 1 (1) 90 (4) 12 (7) ND
Specification of fracture types per cohort in number and percentage
ND not determined, RS Rotterdam Study
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microneurography, was inversely associated with trabecular
microstructure and bone strength in women [38]. Although
both studies indicated that the SNS is involved in the regula-
tion of human bonemetabolism, they provided no information
on the type of adrenergic receptor involved in the signal trans-
duction from the SNS to bone cells. In mice, knockout of
adrenergic receptors, including beta-1, beta-2 [39], beta-3
[40], alpha-2A, and alpha-2C [41], results in distinct bone
phenotypes, but the bone cell-specific effect has only been
demonstrated for the B2AR. The type of adrenergic receptor
involved in human bone metabolism remains largely un-
known. Our data do not support a critical role for the B2AR.
Polymorphisms in the B2AR gene are functionally relevant
in vitro and in vivo [12] in diverse (patho)physiological pro-
cesses. Mitchell et al. examined the genetics of heterotopic
ossification, a skeletal complication in trauma and surgery
patients, and identified an increased risk with a polymorphism
(rs1042714) in the B2AR gene [42]. This suggests an effect of
polymorphisms in the B2AR gene on bone metabolism. A
genome-wide association study on bone mineral density has
been performed, and the identified loci have been tested for an
association with fracture risk, but the B2AR gene was not
identified as a significant contributor in this study [28]. How-
ever, this does not completely exclude the possibility that
polymorphisms in the B2AR gene are involved in bone me-
tabolism. Liu et al. clearly showed in a set of elegant theoret-
ical analyses using simulation studies that the power to iden-
tify certain loci depends, among others, on the number of
causal SNPs, the effect size of the SNP, and the degree of
heterogeneity of the studies [43]. Considering that osteoporo-
sis is a multifactorial disease with probably many causal SNPs
differing in effect size [44] and a considerable amount of het-
erogeneity in the GWAS populations, it remains possible that
polymorphisms in the B2AR gene play a role in bone metab-
olismwithout being identified in a GWAS analysis. Therefore,
candidate gene studies such as ours, based on sound animal
experimental evidence, are still important to perform and
report.
There are several limitations to this study. Subjects in the
UCP cohort had an increased cardiovascular risk, and many
were receiving beta-blockers (79 % of controls and 58 % of
cases), which may have blurred an effect of the polymor-
phisms. Since 90 % of the beta-blockers prescribed were
beta-1 selective with a low affinity for the beta-2 adrenergic
receptor, the effect on the association between polymorphisms
and fracture risk is probably limited. In addition, the lack of
association did not change by adjusting the analysis for the use
of beta-blockers (Table 3). In the UCP cohort, vertebral
Table 3 Genotype and fracture
UCP Rotterdam Study
Odds ratio Odds ratio
Crude estimate 95 % CI p value Adjusted estimate 95 % CI p value Estimate 95 % CI p value
rs1042713 0.94 0.74–1.19 0.591 0.93 0.73–1.18 0.545 0.98 0.91–1.06 0.634
rs1042714 1.14 0.91–1.43 0.262 1.16 0.92–1.46 0.223 1.03 0.96–1.11 0.372
rs1800888 0.58 0.14–2.38 0.445 0.62 0.15–2.65 0.523 1.21 0.86–1.71 0.275
Odds ratios were calculated per copy of the minor allele (rs1042713 Arg/Gly, rs1042714 Gln/Glu, and rs1800888 Thr/Ile)
Fig. 1 Forest plots meta-analysis
UCP and Rotterdam Study co-
horts for polymorphisms in the
B2AR and fracture
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fractures seem underrepresented. This is probably due to the
relatively young age of the cohort (mean 58 years) and the
definition of fracture based on hospital discharge code; verte-
bral fracture patients are not routinely admitted to the hospital
and mostly treated as outpatients. The Rotterdam Study co-
horts, in contrast, contain many fracture patients diagnosed
based on interviewing, status reviews, and imaging. The
follow-up of the Rotterdam Study I comprises over 20 years
of follow-up of inhabitants aged >55 years whereas the
follow-up of the Rotterdam Study II participants started in
2000; this explains the difference in fracture rate between
these populations. The Rotterdam Study III population, started
in 2006 at a younger age of 45, underwent standard X-ray
examinations of vertebral bodies and thus contains only ver-
tebral fractures, underestimating the true fracture rate. How-
ever, vertebral fractures are highly representative of osteopo-
rotic fractures, and the association results for this cohort are
not different from the other two cohorts.
Overall, the populations of the UCP and Rotterdam Study
were comparable, population-based prospective cohorts of
middle-aged subjects. Therefore, in combination, the two co-
horts provide a relevant population with an adequate sample
size to investigate the hypothesis. However, some information
on subject characteristics, such as vitamin D levels, smoking,
BMI, prior fracture, and alcoholism, was not fully available in
both cohorts, and therefore, we could not perform these sec-
ondary analyses. In addition, medication use was determined
at baseline in the Rotterdam Study, and with over 20 years of
follow-up, this could be very different at the time of fracture;
therefore, we did not perform a medication-adjusted analysis
for the Rotterdam Study. In the UCP cohort, medication use
was determined as present if used during follow-up; therefore,
all medication was included. This seems a reliable method for
patients suffering from chronic diseases such as hypertension,
diabetes, and epilepsy, which generally are long-term medica-
tion users, but could influence the results for incident medica-
tions such as sleep medication, known to increase fracture
risk. However, we did observe a higher percentage of sleep
medication use in cases, and considering the crude and adjust-
ed odds ratio’s for the associations between fracture and the
polymorphisms, an effect of medication does not seem very
likely.
The Rotterdam Study included prevalent radiographic ver-
tebral fractures (diagnosed at the start of the study, so there is
difficulty in defining follow-up time) and incident fractures
(not only clinical fractures occurring during the course of the
study but also radiographic vertebral fractures at the follow-up
visit after 4 to 7 years, of which a significant proportion is
asymptomatic, and thus, determining the exact time of fracture
is impossible). Therefore, we chose to analyze the data of the
Rotterdam Study as a case–control study. In addition, applica-
tion of a Cox proportional hazard model to imputed SNP data
requires special methods. The UCP cohort included incident
fractures, occurring during the course of the study with accu-
rate assessment of the fracture date from the hospital discharge
database. Therefore, we re-analyzed the data of the UCP co-
hort using a Cox proportional hazard model, but this did not
change the results.
Finally, although we did not observe any effect of polymor-
phisms in the B2AR gene on fracture risk and bone mineral
density, this does not exclude the possibility of an effect of
these polymorphisms through interaction with other, as yet,
unknown genes. The original studies in mice were performed
in one strain of mice, with the same genetic background. In
humans of course, this is very different and it is difficult to
control for variations in genetic background possibly affecting
the effect of the gene on the outcome. We did analyze haplo-
types, which could account for some genetic background var-
iance; however, this did not change the results.
Furthermore, according to the GWAS studies on fracture,
fracture risk is probably poly-genetically determined, and
thus, interaction of the B2AR gene with other genes is possi-
ble. However, the animal studies showed profound influence
on bone remodeling by the B2AR itself, and we know that the
B2AR is highly conserved among humans and mice. In addi-
tion, we know that polymorphisms in the B2AR by itself
influence receptor function. Therefore, if the B2AR influences
human bone remodeling, we expected at least some effect of
these polymorphisms on fracture risk and bone mineral
density.
During the last decade, several lines of research have
shown a role of the beta-2 adrenergic receptor in bone metab-
olism in rodents. In humans, there is convincing evidence that
the sympathetic nervous system influences bone remodeling,
although the exact mechanism is still unclear. In the present
study, we aimed to elucidate the role of the beta-2 adrenergic
receptor by investigating the effect of polymorphisms on frac-
ture risk in two population-based cohorts and on bone mineral
density using GWA data, but we did not find an association.
For the future, the challenge remains to identify the exact
pathway from the sympathetic nervous system to bone and
to unravel this complex mechanism.
Acknowledgments The Netherlands Organization for Health Research
and Development (ZonMw) provided funding for the analysis of the UCP
database. The generation and management of GWAS genotype data for
the Rotterdam Study were supported by a Netherlands Organization for
Scientific Research (NWO) Investments grant (nr. 175.010.2005.011,
911-03-012). This study was also supported by the Research Institute
for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Geno-
mics Initiative (NGI)/NWO project no. 050-060-810, the Netherlands
Forensic Institute, and by a grant from the NGI/NWO within the frame-
work of the Forensic Genomics Consortium Netherlands. The Rotterdam
Study is funded by the Erasmus University Medical Center, the Erasmus
University Rotterdam, ZonMw, the RIDE, the Ministry of Education,
Culture and Science, the Ministry for Health, Welfare and Sports of the
Netherlands, the European Commission (DG XII), and the Municipality
of Rotterdam. GEFOS is a European Union Seventh Framework Package
funded project registered under grant agreement number: FP7-HEALTH-
Osteoporos Int (2015) 26:2019–2027 2025
F2-2008-201865-GEFOS. A list of members of the GEFOS consortium
who participated in the creation of this dataset can be found online (http://
www.gefos.org/?q=content/data-release).
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
References
1. Kajimura D, Hinoi E, FerronM, Kode A, Riley KJ, ZhouB, GuoXE,
Karsenty G (2011) Genetic determination of the cellular basis of the
sympathetic regulation of bone mass accrual. J Exp Med
2. Toulis KA, Hemming K, Stergianos S, Nirantharakumar K,
Bilezikian JP (2013) +¦-Adrenergic receptor antagonists and fracture
risk: a meta-analysis of selectivity, gender, and site-specific effects.
Osteoporos Int 1–9
3. Rosenbaum DM, Rasmussen SGF, Kobilka BK (2009) The structure
and function of G-protein-coupled receptors. Nature 459:356–63
4. Reihsaus E, Innis M, MacIntyre N, Liggett SB (1993) Mutations in
the gene encoding for the +¦2-adrenergic receptor in normal and asth-
matic subjects. Am J Respir Cell Mol Biol 8:334–39
5. Panebra A, Wang WC, Malone MM, Pitter DR, Weiss ST, Hawkins
GA, Liggett SB (2010) Common ADRB2 haplotypes derived from
26 polymorphic sites direct beta2-adrenergic receptor expression and
regulation phenotypes. PLoS One 5:e11819
6. Liggett SB (2000) Pharmacogenetics of beta-1- and beta-2-
adrenergic receptors. Pharmacology 61:167–73
7. Green SA, Cole G, Jacinto M, Innis M, Liggett SB (1993) A poly-
morphism of the human beta 2-adrenergic receptor within the fourth
transmembrane domain alters ligand binding and functional proper-
ties of the receptor. J Biol Chem 268:23116–21
8. Green SA, Turki J, InnisM, Liggett SB (1994) Amino-terminal poly-
morphisms of the human. beta 2-Adrenergic receptor impart distinct
agonist-promoted regulatory properties. Biochemistry 33:9414–19
9. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB
(1996)Myocardial signaling defects and impaired cardiac function of
a human beta 2-adrenergic receptor polymorphism expressed in
transgenic mice. Proc Natl Acad Sci 93:10483–88
10. Small KM, McGraw DW, Liggett SB (2003) Pharmacology and
physiology of human adrenergic receptor polymorphisms. Annu
Rev Pharmacol Toxicol 43:381–411
11. Ahles A, Engelhardt S (2009) Polymorphisms determine beta-
adrenoceptor conformation: implications for cardiovascular disease
and therapy. Trends Pharmacol Sci 30:188–93
12. Leineweber K, Heusch G (2009) Beta 1- and beta 2-adrenoceptor
polymorphisms and cardiovascular diseases. Br J Pharmacol 158:
61–69
13. Brodde OE (2008) Beta1- and beta2-adrenoceptor polymorphisms
and cardiovascular diseases. Fundam Clin Pharmacol 22:107–25
14. Johnson JA, Liggett SB (2011) Cardiovascular pharmacogenomics
of adrenergic receptor signaling: clinical implications and future di-
rections. Clin Pharmacol Ther 89:366–78
15. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R (1997)
Association between genetic polymorphisms of the beta2-
adrenoceptor and response to albuterol in children with and without
a history of wheezing. J Clin Invest 100:3184–88
16. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF,
Ogston SA, Palmer CNA, Mukhopadhyay S (2013) Tailored
second-line therapy in asthmatic children with the Arg16 genotype.
Clin Sci 124:521–28
17. Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P,
Lannfelt L, Arner P (1997) Human beta-2 adrenoceptor gene poly-
morphisms are highly frequent in obesity and associate with altered
adipocyte beta-2 adrenoceptor function. J Clin Invest 100:3005–13
18. Kulminski AM, Culminskaya I, Ukraintseva SV, Arbeev KG, Land
KC, Yashin AI (2010) Beta2-adrenergic receptor gene polymor-
phisms as systemic determinants of healthy aging in an evolutionary
context. Mech Ageing Dev 131:338–45
19. Adriani KS, BrouwerMC, Baas F, ZwindermanAH, van der Ende A,
van de Beek D (2012) Genetic variation in the +¦2-adrenocepter gene
is associated with susceptibility to bacterial meningitis in adults.
PLoS ONE 7:e37618
20. Chu X, Dong Y, Shen M, Sun L, Dong C, Wang Y, Wang B, Zhang
K, Hua Q, Xu S, Huang W (2009) Polymorphisms in the ADRB2
gene and Graves disease: a case–control study and a meta-analysis of
available evidence. BMC Med Genet 10:26
21. Wieren-de Wijer D, Maitland-van der Zee A-H, Boer A, Stricker B,
Kroon A, Leeuw P, Bozkurt O, Klungel O (2009) Recruitment of
participants through community pharmacies for a pharmacogenetic
study of antihypertensive drug treatment. Pharm World Sci 31:158–
64
22. van Wieren-de Wijer DB, Maitland-van der Zee A-H, de Boer A,
Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van
Duijn CM, Stricker BH, Klungel OH (2009) Interaction between the
Gly460Trp +¦-adducin gene variant and diuretics on the risk of myo-
cardial infarction. J Hypertens 27
23. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner
JT, Galver L, Barrett JC, Grant SFA, Farlow DN, Chandrupatla HR,
HansenM,Ajmal S, PapanicolaouGJ, GuoY, LiM,DerOhannessian
S, de Bakker PIW, Bailey SD, Montpetit A, Edmondson AC, Taylor
K, Gai X, Wang SS, Fornage M, Shaikh T, Groop L, Boehnke M,
Hall AS, Hattersley AT, Frackelton E, Patterson N, Chiang CWK,
Kim CE, Fabsitz RR, Ouwehand W, Price AL, Munroe P, Caulfield
M, Drake T, Boerwinkle E, Reich D, Whitehead AS, Cappola TP,
Samani NJ, Lusis AJ, Schadt E, Wilson JG, Koenig W, McCarthy
MI, Kathiresan S, Gabriel SB, Hakonarson H, Anand SS, Reilly M,
Engert JC, Nickerson DA, Rader DJ, Hirschhorn JN, FitzGerald GA
(2008) Concept, Design and Implementation of a Cardiovascular
Gene-Centric 50 K SNP Array for Large-Scale Genomic
Association Studies. PLoS ONE 3:e3583
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR,
Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC
(2007) PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am J Hum Genet 81:559–75
25. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA,
Reich D (2006) Principal components analysis corrects for stratifica-
tion in genome-wide association studies. Nat Genet 38:904–9
26. Hofman A, Murad S, Duijn C, Franco O, Goedegebure A, Arfan
Ikram M, Klaver C, Nijsten T, Peeters R, Stricker B, Tiemeier H,
Uitterlinden AG, Vernooij M (2013) The Rotterdam Study: 2014
objectives and design update. Eur J Epidemiol 28:889–926
27. (2007) A second generation human haplotype map of over 3.1 mil-
lion SNPs. Nature 449: 851–61
28. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL,
Ntzani EE, Oei L, Albagha OME, Amin N, Kemp JP, Koller DL,
Li G, Liu CT, Minster RL, Moayyeri A, Vandenput L, Willner D,
Xiao SM, Yerges-Armstrong LM, Zheng HF, Alonso N, Eriksson J,
Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG,
Wilson JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR,
Dailiana Z, Duggan DJ, Garcia M, Garcia-Giralt N, Giroux S,
Hallmans G, Hocking LJ, Husted LB, Jameson KA, Khusainova R,
Kim GS, Kooperberg C, Koromila T, Kruk M, Laaksonen M,
LaCroix AZ, Lee SH, Leung PC, Lewis JR, Masi L, Mencej-
Bedrac S, Nguyen TV, Nogues X, Patel MS, Prezelj J, Rose LM,
2026 Osteoporos Int (2015) 26:2019–2027
Scollen S, Siggeirsdottir K, Smith AV, Svensson O, Trompet S,
Trummer O, van Schoor NM, Woo J, Zhu K, Balcells S, Brandi
ML, Buckley BM, Cheng S, Christiansen C, Cooper C, Dedoussis
G, Ford I, Frost M, Goltzman D, Gonzalez-Macias J, Kahonen M,
Karlsson M, Khusnutdinova E, Koh JM, Kollia P, Langdahl BL,
Leslie WD, Lips P, Ljunggren O, Lorenc RS, Marc J, Mellstrom D,
Obermayer-Pietsch B, Olmos JM, Pettersson-Kymmer U, Reid DM,
Riancho JA, Ridker PM, Rousseau F, Lagboom PE, Tang NLS,
Urreizti R, Van Hul W, Viikari J, Zarrabeitia MT, Aulchenko YS,
Castano-Betancourt M, Grundberg E, Herrera L, Ingvarsson T,
Johannsdottir H, Kwan T, Li R, Luben R, Medina-Gomez C, Th
Palsson S, Reppe S, Rotter JI, Sigurdsson G, van Meurs JBJ,
Verlaan D, Williams FMK, Wood AR, Zhou Y, Gautvik KM,
Pastinen T, Raychaudhuri S, Cauley JA, Chasman DI, Clark GR,
Cummings SR, Danoy P, Dennison EM, Eastell R, Eisman JA,
Gudnason V, Hofman A, Jackson RD, Jones G, Jukema JW, Khaw
KT, Lehtimaki T, Liu Y, Lorentzon M, McCloskey E, Mitchell BD,
Nandakumar K, Nicholson GC, Oostra BA, Peacock M, Pols HAP,
Prince RL, Raitakari O, Reid IR, Robbins J, Sambrook PN, Sham
PC, Shuldiner AR, Tylavsky FA, van Duijn CM, Wareham NJ,
Cupples LA, Econs MJ, Evans DM, Harris TB, Kung AWC, Psaty
BM, Reeve J, Spector TD, Streeten EA, Zillikens MC,
Thorsteinsdottir U, Ohlsson C, Karasik D, Richards JB, Brown
MA, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JPA,
Kiel DP, Rivadeneira F (2012) Genome-widemeta-analysis identifies
56 bone mineral density loci and reveals 14 loci associated with risk
of fracture. Nat Genet 44:491–501
29. Li Y DJAG (2006) Mach 1.0: Rapid haplotype reconstruction and
missing genotype inference. Abstract 2290, presented at the annual
meeting of the American Society of Human Genetics, New Orleans
30. Estrada K, Abuseiris A, Grosveld FG, Uitterlinden AG, Knoch TA,
Rivadeneira F (2009) GRIMP: a web- and grid-based tool for high-
speed analysis of large-scale genome-wide association using imputed
data. Bioinformatics 25:2750–2752
31. R Core Team (2013) R: A language and environment for statistical
computing
32. Sinnwell JP, Schaid DJ (2013) haplo.stats: statistical analysis of hap-
lotypes with traits and covariates when linkage phase is ambiguous
33. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo
H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C,
Karsenty G (2005) Leptin regulation of bone resorption by the sym-
pathetic nervous system and CART. Nature 434:514–20
34. Arai M, Sato T, Takeuchi S, Goto S, Togari A (2013) Dose effects of
butoxamine, a selective +¦2-adrenoceptor antagonist, on bone metab-
olism in spontaneously hypertensive rat. Eur J Pharmacol 701:7–13
35. Kondo H, Togari A (2011) Continuous treatment with a low-dose +¦-
agonist reduces bone mass by increasing bone resorption without
suppressing bone formation. Calcif Tissue Int 88:23–32
36. Bonnet N, Benhamou CL, Brunet-Imbault B, Arlettaz A, Horcajada
MN, Richard O, Vico L, Collomp K, Courteix D (2005) Severe bone
alterations under beta2 agonist treatments: bone mass,
microarchitecture and strength analyses in female rats. Bone 37:
622–33
37. Veldhuis-Vlug AG, El Mahdiui M, Endert E, Heijboer AC, Fliers E,
Bisschop PH (2012) Bone resorption is increased in pheochromocy-
toma patients and normalizes following adrenalectomy. J Clin
Endocrinol Metab 97:E2093–E2097
38. Farr JN, Charkoudian N, Barnes JN, Monroe DG, McCready LK,
Atkinson EJ, Amin S, Melton LJ, Joyner MJ, Khosla S (2012)
Relationship of sympathetic activity to bonemicrostructure, turnover,
and plasma osteopontin levels in women. J Clin Endocrinol Metab
97:4219–27
39. Pierroz DD, Bonnet N, Bianchi EN, Bouxsein ML, Baldock PA,
Rizzoli R, Ferrari SL (2012) Deletion of +¦-adrenergic receptor 1, 2,
or both leads to different bone phenotypes and response to mechan-
ical stimulation. J Bone Miner Res 27:1252–62
40. BouxseinML, DevlinMJ, Glatt V, Dhillon H, Pierroz DD, Ferrari SL
(2009) Mice lacking beta-adrenergic receptors have increased bone
mass but are not protected from deleterious skeletal effects of ovari-
ectomy. Endocrinology 150:144–52
41. Fonseca TL, Jorgetti V, Costa CC, Capelo LP, Covarrubias AE,
Moulatlet AC, Teixeira MB, Hesse E, Morethson P, Beber EH,
Freitas FR, Wang CC, Nonaka KO, Oliveira R, Casarini DE, Zorn
TM, Brum PC, Gouveia CH (2011) Double disruption of +¦2A- and +
¦2C -adrenoceptors results in sympathetic hyperactivity and high-
bone-mass phenotype. J Bone Miner Res 26:591–603
42. Mitchell EJ, Canter J, Norris P, Jenkins J, Morris J (2010) The genet-
ics of heterotopic ossification: insight into the bone remodeling path-
way. J Orthop Trauma 24:530–533
43. Liu YJ, Zhang L, Pei Y, Papasian CJ, Deng HW (2013) On genome-
wide association studies and their meta-analyses: lessons learned
from osteoporosis studies. J Clin Endocrinol Metab 98:E1278–
E1282
44. Ralston SH, Uitterlinden AG (2010) Genetics of osteoporosis.
Endocr Rev 31:629–62
Osteoporos Int (2015) 26:2019–2027 2027
